Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodney J Baber

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Climacteric : the Journal of the International Menopause Society|March 2, 2018
Editor's commentRodney J Baber
Nature Reviews. Endocrinology|May 27, 2022
Treating menopause - MHT and beyondSusan R Davis, Rodney J Baber
Climacteric : the Journal of the International Menopause Society|January 18, 2021
Managing the menopause: the question of evidenceJames H Pickar, Rodney J Baber
Journal of Multidisciplinary Healthcare|June 20, 2015
Ethical implications of digital images for teaching and learning purposes: an integrative reviewRachel Kornhaber, Vasiliki Betihavas, Rodney J Baber
BMJ (Clinical Research Ed.)|April 16, 2002
Hormone replacement therapy and the breast. Studies must determine the evidenceAlastair H MacLennan, Beverley Lawton, Rodney J Baber
Journal of Medical Case Reports|February 12, 2009
Vernix caseosa peritonitis - no longer rare or innocent: a case seriesOlivia A Stuart, Alastair R Morris, Rodney J Baber
International Journal of Nanomedicine|August 11, 2015
Ongoing ethical issues concerning authorship in biomedical journals: an integrative reviewRachel Anne Kornhaber, Loyola M McLean, Rodney J Baber
The Medical Journal of Australia|June 12, 2003
Hormone replacement therapy: to use or not to use?Rodney J Baber, Justine L O'Hara, Frances M Boyle
The Journal of Clinical Endocrinology and Metabolism|January 23, 2021
Letter to the Editor: "Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline"Susan R Davis, Bronwyn G A Stuckey, Karen S Magraith, et al.
Lancet (London, England)|November 11, 2022
Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trialAmanda Vrselja, Ardian Latifi, Rodney J Baber, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Climacteric : the Journal of the International Menopause Society|March 2, 2018
Editor's commentRodney J Baber
Nature Reviews. Endocrinology|May 27, 2022
Treating menopause - MHT and beyondSusan R Davis, Rodney J Baber
Climacteric : the Journal of the International Menopause Society|January 18, 2021
Managing the menopause: the question of evidenceJames H Pickar, Rodney J Baber
Journal of Multidisciplinary Healthcare|June 20, 2015
Ethical implications of digital images for teaching and learning purposes: an integrative reviewRachel Kornhaber, Vasiliki Betihavas, Rodney J Baber
BMJ (Clinical Research Ed.)|April 16, 2002
Hormone replacement therapy and the breast. Studies must determine the evidenceAlastair H MacLennan, Beverley Lawton, Rodney J Baber
Journal of Medical Case Reports|February 12, 2009
Vernix caseosa peritonitis - no longer rare or innocent: a case seriesOlivia A Stuart, Alastair R Morris, Rodney J Baber
International Journal of Nanomedicine|August 11, 2015
Ongoing ethical issues concerning authorship in biomedical journals: an integrative reviewRachel Anne Kornhaber, Loyola M McLean, Rodney J Baber
The Medical Journal of Australia|June 12, 2003
Hormone replacement therapy: to use or not to use?Rodney J Baber, Justine L O'Hara, Frances M Boyle
The Journal of Clinical Endocrinology and Metabolism|January 23, 2021
Letter to the Editor: "Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline"Susan R Davis, Bronwyn G A Stuckey, Karen S Magraith, et al.
Lancet (London, England)|November 11, 2022
Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trialAmanda Vrselja, Ardian Latifi, Rodney J Baber, et al.
Pageof 2